Acts Online
GT Shield

Medicines and Related Substances Control Act, 1965 (Act No. 101 of 1965)

Regulations

General Regulations

Supply of Medicines

3. Conditions for compounding medicine

 

(1) A pharmacist—
(a) compounding  a medicine for sale in terms of section 14(4) of the Act must only compound a quantity that is related to a treatment regimen of a particular person or animal to be used by the person or for the animal  for not more than 30 consecutive days from the date of sale;
(b) must indicate clearly on the label of a medicine compounded for sale in the retail trade in terms of section 14(4)(b) of the Act the—
(i) dates of compounding and sale; and
(ii) statement "Use within X days", where X relates to the number of days within which the medicine should be used; and
(c) may, in the case of medicine intended for the retail trade, based on the amount of medicine compounded previously for a particular period, compound such medicine in anticipation of supply thereof within such particular period.

[Regulation 3 substituted by section 3(a) of Notice No. 2853, GG47673, dated 8 December 2022]

 

(2) Any medicine compounded in terms of section 14(4) may not be advertised or displayed for sale.

 

(3) No medicine may be compounded by a pharmacist, veterinarian or a person licensed in terms of section 22C(1)(a) of the Act to compound a medicine for sale—

[Words preceding (3)(a) regulation 3 substituted by section 3(b) of Notice No. 2853, GG47673, dated 8 December 2022]

(a) [Regulation 3(a) deleted by section 3(c) of Notice No. 2853, GG47673, dated 8 December 2022];
(b) which has been declared undesirable in terms of section 23 of the Act or prohibited in terms of section 36A of the Act in the case of a veterinary medicine;

[Regulation 3(b) substituted by section 3(d) of Notice No. 2853, GG47673, dated 8 December 2022]

(c) for the purpose of growth promotion or performance enhancement;
(d) for the purpose of administering to food-producing animals if—
(i) Maximum Residue Limits (MRL); and
(ii) appropriate withdrawal times,

have not been established;

(e) for use by a patient not under the professional care of an authorised prescriber or pharmacist;
(f) [Regulation 3(f) deleted by section 3(e) of Notice No. 2853, GG47673, dated 8 December 2022];
(g) unless the compounding thereof is performed in accordance with good compounding as determined by the Authority.

[Regulation 3(g) substituted by section 3(f) of Notice No. 2853, GG47673, dated 8 December 2022]

 

Publication of guidelines

 

(4) The Authority must Within six (6) months of the date of publication of this regulation in the government gazette, publish draft guidelines on good compounding practice for public comment.

[Regulation 3(4) (Publication of guidelines) inserted by section 4 of Notice No. 2853, GG47673, dated 8 December 2022]